Liver Cancer (LC) (Project-003)

肝癌 (LC)（项目-003）

• 批准号: 8932193
• 负责人: SCOTT L. FRIEDMAN
• 金额: $ 0.66万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8932193
• 关键词: Address; Alcoholic Liver Diseases; Award; Basic Science; Biliary; Cancer Center Support Grant; Cancer Research Project; Caring; Chronic; Classification; Clinical; Clinical Research; Clinical Trials; Communities; Community Outreach; Data; Development; Diagnosis; Disease; Enrollment; Epigenetic Process; Fatty Liver; Fibrosis; Genomics; Goals; Hepatic; Hepatitis; Hepatitis B Virus; Hepatitis C virus; Hepatocarcinogenesis; Inflammation; Institutes; Intervention; Intrahepatic Cholangiocarcinoma; Investigation; Laboratory Study; Lead; Link; Liver; Liver Fibrosis; Liver diseases; Malignant Neoplasms; Malignant neoplasm of liver; Modeling; Molecular; Molecular Diagnosis; Mus; Newly Diagnosed; Operative Surgical Procedures; Pathogenesis; Patients; Peer Review; Positioning Attribute; Preventive; Primary carcinoma of the liver cells; Proteomics; Publishing; Randomized; Reporting; Research Personnel; Risk; Scientist; Serum; Signal Pathway; Stratification; Testing; Therapeutic; Tissues; Translating; Translational Research; Underserved Population; United States; Viral hepatitis; Zebrafish; abstracting; base; chronic liver disease; efficacy testing; improved; innovation; member; multidisciplinary; novel; novel strategies; outreach program; personalized medicine; pre-clinical; preclinical study; programs; screening; translational study

ABSTRACT – LIVER CANCER (LC) RESEARCH PROGRAM Program Leaders: Scott Friedman, MD and Josep Llovet, MD The Liver Cancer (LC) Program is a comprehensive multidisciplinary program that incorporates all aspects of the disease from community screening to fundamental mechanisms of heptocarcinogenesis in both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The objectives of this program are to: 1) Elucidate fundamental mechanisms underlying the basis of how chronic liver or biliary disease and fibrosis precipitously increase the risk of HCC and ICC; 2) Translate these fundamental advances into novel approaches to the diagnosis and molecular stratification of HCC and ICC; 3) Test the efficacy of these novel interventions in investigator-initiated, early clinical proof-of concept trials and subsequently in pivotal randomized studies. The themes that have developed from this focus are: 1) Basic mechanisms of chronic hepatic inflammation that lead to HCC; 2) Molecular and cellular basis of hepatic fibrosis and HCC; 2) Novel models and pre-clinical studies of HCC pathogenesis and treatment; 3) Innovative therapeutic pre-clinical and clinical strategies for liver cancer (HCC and ICC). Highlights of the program include: a) Established comprehensive community outreach programs devoted to screening for chronic liver disease among underserved populations, linked to care for newly diagnosed liver disease; b) Unique clinical expertise in the preventive management of patients with chronic liver disease through hepatitis treatments and surgical care of HCC; c) A basic and translational research program that is redefining the molecular classification of HCC and ICC; d) A fruitful HCC tissue and serum bank that provides Mount Sinai scientists and investigators throughout the world with unique sets of genomic, proteomic and epigenetic data; e) A robust clinical trials program in HCC and ICC that has led the United States in enrollment in HCC clinical trials. The program is uniquely positioned to achieve its long-term goal to generate groundbreaking advances in understanding mechanisms of HCC and ICC, and to apply these towards the development and early testing of novel, personalized therapies that will improve the outlook for patients with these catastrophic malignancies The LC program has 24 members, and they represent 10 departments and 6 institutes. As of July 1, 2014, program members were awarded $3,124,363 in NCI and other peer-reviewed cancer-related direct support. Since 2011, LC program members published 220 reports, of which 28.6% were intra-programmatic and 8.2% inter-programmatic.

摘要 - 肝癌（LC）研究计划 计划负责人：医学博士Scott Friedman和医学博士Josep Llovet 肝癌（LC）计划是一个综合的多学科计划，结合了 从社区筛查到两者的甲基卡诺生成的基本机制的疾病 肝细胞癌（HCC）和肝内胆管癌（ICC）。该程序的目标 为：1）阐明慢性肝或胆道疾病和 纤维化精确增加了HCC和ICC的风险； 2）将这些基本进步转化为新颖 HCC和ICC诊断和分子分层的方法； 3）测试这些小说的效率 研究人员发起的早期临床概念证明试验的干预措施，随后在关键 随机研究。 从此重点发展的主题是：1）慢性肝注射的基本机制 这导致了HCC； 2）肝纤维化和HCC的分子和细胞基础； 2）新颖的模型和临床前 HCC发病机理和治疗的研究； 3）创新的治疗性治疗前临床和临床策略 肝癌（HCC和ICC）。该计划的亮点包括：a）既定的综合社区 外展计划致力于筛查服务不足的人群中的慢性肝病，与 照顾新诊断的肝病； b）患者预防治疗方面的独特临床专业知识 通过肝炎治疗和HCC手术护理患有慢性肝病； c）基本和翻译 重新定义HCC和ICC分子分类的研究计划； d）富有成果的HCC组织和 血清库为全世界的西奈山科学家和调查人员提供独特的集合 基因组，蛋白质组学和表观遗传学数据； e）在HCC和ICC中的强大临床试验计划领导 美国参加HCC临床试验。该计划的独特位置可以实现其长期 在理解HCC和ICC机制方面产生突破性的进步，并应用这些机制 采取新颖，个性化疗法的开发和早期测试，这些疗法将改善前景 这些灾难性恶性肿瘤的患者 LC计划有24名成员，他们代表10个部门和6个机构。截至2014年7月1日， 计划成员在NCI和其他与癌症相关的直接支持中获得了3,124,363美元的授予。 自2011年以来，LC计划成员发表了220个报告，其中28.6％是概括性内的，并且 8.2％的截面。